CA2034569A1 - Oral pharmaceutical forms of pimobendan - Google Patents
Oral pharmaceutical forms of pimobendanInfo
- Publication number
- CA2034569A1 CA2034569A1 CA002034569A CA2034569A CA2034569A1 CA 2034569 A1 CA2034569 A1 CA 2034569A1 CA 002034569 A CA002034569 A CA 002034569A CA 2034569 A CA2034569 A CA 2034569A CA 2034569 A1 CA2034569 A1 CA 2034569A1
- Authority
- CA
- Canada
- Prior art keywords
- pimobendan
- oral pharmaceutical
- pharmaceutical forms
- fluctuations
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002164 pimobendan Drugs 0.000 title abstract 2
- GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 title abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Constant, satisfactory resorption of pimobendan is ensured even when there are major pH fluctuations in the gastrointestinal tract, when it is formulated for oral administration together with citric acid.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4001622.6 | 1990-01-20 | ||
| DE4001622A DE4001622A1 (en) | 1990-01-20 | 1990-01-20 | ORAL DRUGS OF PIMOBENDAN |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2034569A1 true CA2034569A1 (en) | 1991-07-21 |
| CA2034569C CA2034569C (en) | 2002-03-19 |
Family
ID=6398467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002034569A Expired - Lifetime CA2034569C (en) | 1990-01-20 | 1991-01-18 | Oral pharmaceutical forms of pimobendan |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0439030B1 (en) |
| JP (1) | JP2608183B2 (en) |
| KR (1) | KR0163056B1 (en) |
| AT (1) | ATE87481T1 (en) |
| AU (1) | AU630536B2 (en) |
| CA (1) | CA2034569C (en) |
| DE (2) | DE4001622A1 (en) |
| DK (1) | DK0439030T3 (en) |
| ES (1) | ES2054379T3 (en) |
| FI (1) | FI96274C (en) |
| HK (1) | HK175796A (en) |
| HU (1) | HU207948B (en) |
| IE (1) | IE64659B1 (en) |
| IL (1) | IL96995A (en) |
| NO (1) | NO176305C (en) |
| NZ (1) | NZ236834A (en) |
| PT (1) | PT96506B (en) |
| ZA (1) | ZA91372B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8664252B2 (en) | 2008-11-25 | 2014-03-04 | Boehringer Ingelheim Vetmedica Gmbh | Phosphodiesterase type III (PDE III) inhibitors or CA2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy |
| US8846680B2 (en) | 2004-03-08 | 2014-09-30 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical composition comprising pimobendan |
| US9107952B2 (en) | 2006-11-07 | 2015-08-18 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising pimobendan |
| US9889148B2 (en) | 2004-03-25 | 2018-02-13 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size in mammals suffering from heart failure |
| US10071162B2 (en) | 2013-07-19 | 2018-09-11 | Boehringer Ingelheim Vetmedica Gmbh | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| US10117869B2 (en) | 2004-03-25 | 2018-11-06 | Boehringer Ingelheim Vetmedica Gmbh | PDE III inhibitors for treatment of asymptomatic heart failure |
| US10172804B2 (en) | 2013-12-04 | 2019-01-08 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical compositions of pimobendan |
| US10398705B2 (en) | 2012-03-15 | 2019-09-03 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2753904B1 (en) * | 1996-10-01 | 1998-10-30 | Gattefosse Ets Sa | PHARMACEUTICAL COMPOSITION WITH MODIFIED RELEASE OF ACTIVE SUBSTANCE, INCLUDING A MATRIX, AND MANUFACTURING PROCESS |
| EP1744750A2 (en) * | 2004-05-06 | 2007-01-24 | Sandoz AG | Pharmaceutical composition comprising hydrophobic drug having improved solubility |
| WO2005123040A1 (en) * | 2004-06-22 | 2005-12-29 | Shionogi & Co., Ltd. | Tablet rapidly disintegrating in mouth |
| JP4572296B2 (en) * | 2004-07-21 | 2010-11-04 | トーアエイヨー株式会社 | Pimobendan oral dosage formulation |
| JP2006028130A (en) * | 2004-07-21 | 2006-02-02 | Toa Eiyo Ltd | Pimobendan oral dosage formulation |
| JP4572293B2 (en) * | 2004-07-21 | 2010-11-04 | トーアエイヨー株式会社 | Pimobendan oral dosage formulation |
| EP1937270A1 (en) * | 2005-09-21 | 2008-07-02 | Brystol-Myers Squibb Company | Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof |
| JP4572300B2 (en) * | 2006-01-19 | 2010-11-04 | トーアエイヨー株式会社 | Pimobendan oral dosage formulation |
| PE20081482A1 (en) * | 2006-12-20 | 2008-12-23 | Novartis Ag | GELATINE CAPSULES CONTAINING AN ACID |
| FR2934156B1 (en) | 2008-07-23 | 2010-09-24 | Virbac | ORAL ADMINISTRATION MEDICAMENT IN SOLID FORM |
| WO2010055119A2 (en) * | 2008-11-17 | 2010-05-20 | Novartis Ag | Pharmaceutical composition comprising pimobendan |
| NL1037569C2 (en) | 2009-12-18 | 2011-06-21 | Eurovet Animal Health B V | Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use. |
| WO2011081118A1 (en) * | 2009-12-29 | 2011-07-07 | 興和株式会社 | Pharmaceutical composition for oral administration |
| JPWO2011081117A1 (en) * | 2009-12-29 | 2013-05-09 | 興和株式会社 | Solid pharmaceutical composition for oral administration |
| CN106729723A (en) * | 2016-11-21 | 2017-05-31 | 青岛农业大学 | A kind of pharmaceutical composition containing UD-CG115BS.acardi and preparation method thereof |
| KR20220006776A (en) * | 2020-07-09 | 2022-01-18 | 주식회사유한양행 | Pharmaceutical compositions comprising a diaminopyrimidine derivative or pharmaceutically acceptable salt thereof and processes for preparing the same |
| EP4633607A1 (en) | 2022-12-15 | 2025-10-22 | Boehringer Ingelheim Vetmedica GmbH | Solid dispersions comprising amorphous pimobendan and one or more stabilizing polymers |
| JP7659339B1 (en) | 2023-11-21 | 2025-04-09 | 東海カプセル株式会社 | Oral film formulation containing pimobendan |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES482789A0 (en) * | 1978-08-25 | 1980-12-01 | Thomae Gmbh Dr K | PROCEDURE FOR THE PREPARATION OF NEW BENZHIMIDAZOLES REPLACED IN POSITION 5 OR 6 WITH A PYRIDAZINONE RING |
| DE2837161A1 (en) * | 1978-08-25 | 1980-03-06 | Thomae Gmbh Dr K | 5-Alkyl:pyridazinyl substd. benzimidazole derivs. - useful as cardiovascular agents, antivirals, interferon inducers and ulcer inhibitors |
| JPS56110612A (en) * | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Readily disintegrable and absorbable compression molded article of slightly soluble drug |
| JPS60163823A (en) * | 1984-02-03 | 1985-08-26 | Taisho Pharmaceut Co Ltd | Orally administered formulation |
| ATE71833T1 (en) * | 1986-11-03 | 1992-02-15 | Schering Corp | LABETALOL DELAYED-RELEASE TABLET. |
| DE3728244A1 (en) * | 1987-08-25 | 1989-03-09 | Thomae Gmbh Dr K | NEW (-) - BENZIMIDAZOLE, THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS |
| EP0306846A3 (en) * | 1987-09-11 | 1990-05-02 | Dr. Karl Thomae GmbH | Synergistic combination comprising a phosphodiesterase inhibitor and a thromboxane-a2 antagonist, and its use or preparation |
| DE3805635A1 (en) * | 1988-02-24 | 1989-09-07 | Thomae Gmbh Dr K | USE OF BENZIMIDAZOLES FOR THE MANUFACTURE OF A MEDICAMENT WITH ANTI-MIXIC EFFECTS ON THE HEART AND ITS COMBINATIONS WITH SS-BLOCKERS OR BRADYCARDICA |
| JPH01258621A (en) * | 1988-04-06 | 1989-10-16 | Fujimoto Seiyaku Kk | Dilazep tablet with regulated absorption |
| JPH023609A (en) * | 1988-06-21 | 1990-01-09 | Fujimoto Seiyaku Kk | Long-acting drug preparation containing nicardipine hydrochloride as active component |
-
1990
- 1990-01-20 DE DE4001622A patent/DE4001622A1/en not_active Withdrawn
-
1991
- 1991-01-11 AT AT91100309T patent/ATE87481T1/en not_active IP Right Cessation
- 1991-01-11 DK DK91100309.3T patent/DK0439030T3/en active
- 1991-01-11 ES ES91100309T patent/ES2054379T3/en not_active Expired - Lifetime
- 1991-01-11 EP EP91100309A patent/EP0439030B1/en not_active Expired - Lifetime
- 1991-01-11 DE DE9191100309T patent/DE59100067D1/en not_active Expired - Lifetime
- 1991-01-17 PT PT96506A patent/PT96506B/en not_active IP Right Cessation
- 1991-01-18 CA CA002034569A patent/CA2034569C/en not_active Expired - Lifetime
- 1991-01-18 HU HU91177A patent/HU207948B/en unknown
- 1991-01-18 FI FI910263A patent/FI96274C/en active
- 1991-01-18 AU AU69454/91A patent/AU630536B2/en not_active Expired
- 1991-01-18 NZ NZ236834A patent/NZ236834A/en unknown
- 1991-01-18 JP JP3004069A patent/JP2608183B2/en not_active Expired - Lifetime
- 1991-01-18 ZA ZA91372A patent/ZA91372B/en unknown
- 1991-01-18 NO NO910213A patent/NO176305C/en not_active IP Right Cessation
- 1991-01-18 IE IE16591A patent/IE64659B1/en not_active IP Right Cessation
- 1991-01-18 KR KR1019910000822A patent/KR0163056B1/en not_active Expired - Lifetime
- 1991-01-22 IL IL9699591A patent/IL96995A/en not_active IP Right Cessation
-
1996
- 1996-09-19 HK HK175796A patent/HK175796A/en not_active IP Right Cessation
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8846680B2 (en) | 2004-03-08 | 2014-09-30 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical composition comprising pimobendan |
| US8846679B2 (en) | 2004-03-08 | 2014-09-30 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical composition comprising pimobendan |
| US8859554B2 (en) | 2004-03-08 | 2014-10-14 | Boehringer Ingelheim Vetmedica Gmbh | Packaging assembly for pharmaceutical composition including pimobendan |
| US10537588B2 (en) | 2004-03-25 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size in mammals suffering from heart failure |
| US9889148B2 (en) | 2004-03-25 | 2018-02-13 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size in mammals suffering from heart failure |
| US11413285B2 (en) | 2004-03-25 | 2022-08-16 | Boehringer Ingelheim Vetmedica Gmbh | PDE III inhibitors for treatment of asymptomatic heart failure |
| US10117869B2 (en) | 2004-03-25 | 2018-11-06 | Boehringer Ingelheim Vetmedica Gmbh | PDE III inhibitors for treatment of asymptomatic heart failure |
| US9107952B2 (en) | 2006-11-07 | 2015-08-18 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising pimobendan |
| US9616134B2 (en) | 2006-11-07 | 2017-04-11 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising pimobendan |
| US10639305B2 (en) | 2006-11-07 | 2020-05-05 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising pimobendan |
| US8664252B2 (en) | 2008-11-25 | 2014-03-04 | Boehringer Ingelheim Vetmedica Gmbh | Phosphodiesterase type III (PDE III) inhibitors or CA2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy |
| US10398705B2 (en) | 2012-03-15 | 2019-09-03 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| US11185590B2 (en) | 2013-07-19 | 2021-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| US10071162B2 (en) | 2013-07-19 | 2018-09-11 | Boehringer Ingelheim Vetmedica Gmbh | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| US12357696B2 (en) | 2013-07-19 | 2025-07-15 | Boehringer Ingelheim Vetmedica Gmbh | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| US10172804B2 (en) | 2013-12-04 | 2019-01-08 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical compositions of pimobendan |
| US10653633B2 (en) | 2013-12-04 | 2020-05-19 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical compositions of pimobendan |
| US10874620B2 (en) | 2013-12-04 | 2020-12-29 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical compositions of pimobendan |
| US11298325B2 (en) | 2013-12-04 | 2022-04-12 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical compositions of pimobendan |
| US12257350B2 (en) | 2013-12-04 | 2025-03-25 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical compositions of pimobendan |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| US12011441B2 (en) | 2016-04-06 | 2024-06-18 | Boehringer Ingelheim Vetmedica Gmbh | Pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
Also Published As
| Publication number | Publication date |
|---|---|
| NO910213D0 (en) | 1991-01-18 |
| IE910165A1 (en) | 1991-07-31 |
| PT96506A (en) | 1991-10-15 |
| FI910263A0 (en) | 1991-01-18 |
| JPH04210919A (en) | 1992-08-03 |
| KR910014120A (en) | 1991-08-31 |
| FI910263L (en) | 1991-07-21 |
| DE4001622A1 (en) | 1991-07-25 |
| CA2034569C (en) | 2002-03-19 |
| NO176305C (en) | 1995-03-15 |
| AU6945491A (en) | 1991-07-25 |
| IE64659B1 (en) | 1995-08-23 |
| IL96995A (en) | 1994-11-11 |
| HU910177D0 (en) | 1991-08-28 |
| EP0439030B1 (en) | 1993-03-31 |
| NZ236834A (en) | 1995-10-26 |
| FI96274C (en) | 1996-06-10 |
| PT96506B (en) | 1998-06-30 |
| EP0439030A3 (en) | 1991-10-16 |
| HU207948B (en) | 1993-07-28 |
| NO910213L (en) | 1991-07-22 |
| HUT56494A (en) | 1991-09-30 |
| EP0439030A2 (en) | 1991-07-31 |
| AU630536B2 (en) | 1992-10-29 |
| HK175796A (en) | 1996-09-27 |
| JP2608183B2 (en) | 1997-05-07 |
| ATE87481T1 (en) | 1993-04-15 |
| FI96274B (en) | 1996-02-29 |
| ZA91372B (en) | 1992-09-30 |
| NO176305B (en) | 1994-12-05 |
| KR0163056B1 (en) | 1998-12-01 |
| DE59100067D1 (en) | 1993-05-06 |
| ES2054379T3 (en) | 1994-08-01 |
| IL96995A0 (en) | 1992-03-29 |
| DK0439030T3 (en) | 1993-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2034569A1 (en) | Oral pharmaceutical forms of pimobendan | |
| CA2194564A1 (en) | Aqueous Risperidone Formulations | |
| CA2005986A1 (en) | Benzimidazole derivative with gastric acid inhibitory effect and process for its preparation | |
| MY110110A (en) | Pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and cns disorders | |
| EP0826376A4 (en) | COMPOSITION FOR ORAL ADMINISTRATION | |
| ITBO910024A1 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING GLYCOSAMINOGLICANS ABSORBABLE ORALLY. | |
| WO1997045091A3 (en) | Sustained release oxycodone formulations with no fed/fast effect | |
| CA2310585A1 (en) | Novel administration form comprising an acid-labile active compound | |
| YU17700A (en) | Oral copositions of levosimendan | |
| IE820856L (en) | Omega-cyano-1,omega-diphenyl-azaalkane derivatives. | |
| CA2328280A1 (en) | Thienopyrimidines | |
| CA2340054A1 (en) | Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles | |
| CA2148671A1 (en) | Stable Crystalline (6S)-and (6R)-Tetrahydrofolic Acid | |
| CA2281054A1 (en) | Combination of zinc ions and vitamin c and method of making | |
| AU4059485A (en) | Substituted benzopyrans | |
| FR2698268B1 (en) | Photoprotective composition administered orally. | |
| ITMI911880A1 (en) | METHOD FOR THE PREPARATION OF ORAL PHARMACEUTICAL FORMS WITH EXTENDED RELEASE CONTAINING ACTIVE SUBSTANCES SOLUBILITY DEPENDENT ON THE PH VALUE. | |
| DE69213183D1 (en) | N'-cyanomethylethylenediamine-N, N'-diacetic acid, their salts and their preparation | |
| EP0331092A3 (en) | Alpha-amino-carboxylic-acid derivatives, their preparation and use | |
| AU563822B2 (en) | Pharmaceutical composition of piroxicam and 5'-guanylic acid or n-acetyl-l-methionine | |
| EP0313945A3 (en) | Medicament for the treatment of hypertension and cardiac insufficiency | |
| IE813100L (en) | Naphthyridine derivatives | |
| CA2101548A1 (en) | Acylamino-alkylidenhydroxy-bisphosphonic acids useful in the therapy of osteoarticular diseases | |
| AU2403592A (en) | 2-aza-2-desamino analogues of 5,8-dideazafolic acid | |
| ITTO960094V0 (en) | INFUSION KIT, ESPECIALLY FOR THE PARENTAL ADMINISTRATION OF THIOCTIC ACID. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |